Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)

Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and efficacy. Here, we assessed the impact of anti‐drug antibodies (ADA) on the PK of the immune checkpoint inhibitor atezolizumab (a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Benjamin, Sternheim, Nitzan, Agarwal, Priya, Suchomel, Julia, Vadhavkar, Shweta, Bruno, Rene, Ballinger, Marcus, Bernaards, Coen A., Chan, Phyllis, Ruppel, Jane, Jin, Jin, Girish, Sandhya, Joshi, Amita, Quarmby, Valerie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742635/
https://www.ncbi.nlm.nih.gov/pubmed/34432389
http://dx.doi.org/10.1111/cts.13127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742635/
https://www.ncbi.nlm.nih.gov/pubmed/34432389
http://dx.doi.org/10.1111/cts.13127

Ejemplares similares